Recent news on

QLT'S Shareholders Elect Philip Livingston to the Board of Directors  -  May 18, 2007
PharmaLive.com (press release),In addition, we utilize two unique technology platforms, photodynamic therapy and Atrigel(R), to create products such as Visudyne(R) and Eligard(R).

QLT strengthens its expertise in ocular by adding David A ...  -  May 1, 2007
Earthtimes.orgAtrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of Novartis AG. Eligard is a registered trademark of Sanofi-aventis.

QLT Announces Q1 Results for 2007  -  Apr 25, 2007
PharmaLive.com (press release),Eligard(R) worldwide sales for the first quarter were $41.8 million, up 145.6% from the first quarter of 2006. Eligard sales in the US were $19.5 million,

QLT Announces that CHMP Will Recommend to the European Commission ...  -  Apr 25, 2007
PharmaLive.com (press release),In addition, we utilize two unique technology platforms, photodynamic therapy and Atrigel(R), to create products such as Visudyne(R) and Eligard(R).

QLT announces first quarter 2007 Visudyne(R) sales  -  Apr 22, 2007
Canada NewsWire (press release),Eligard is a registered trademark of Sanofi-Synthelabo Inc. QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto

MediGene Announces Annual Result for 2006  -  Mar 28, 2007
PharmaLive.com (press release),Revenues amounted to 31.2 million EUR (2005: 19.7 million EUR) and were generated mainly from the commercialization of the drug Eligard®, and a license

DOR BioPharma to test oral drug delivery system  -  Apr 6, 2007
South Florida Business Journal,Marketed as Lupron and Eligard, this drug had worldwide sales of about $1.8 billion in 2006, DOR BioPharma said. Since Leuprolide must be injected,

DOR BioPharma Announces Initiation of Clinical Development Program ...  -  Apr 4, 2007
WM Experts (press release),Injectable forms of leuprolide marketed under tradenames such as Lupron® and Eligard® had worldwide sales of approximately $1.8 billion in 2006.

DOR's oral leuprolide to start trials mid-year  -  Apr 11, 2007
In-PharmaTechnologist.com,Leuprolide, which generated worldwide sales of around US$1.8 billion last year under brand names such as Lupron (TAP Pharmaceutical Products) and Eligard

German Stocks Fall, Led by Volkswagen, Siemens and Allianz  -  Mar 28, 2007
BloombergThe biotechnology company said its full-year loss narrowed to 6.9 million euros on the sale of its prostate cancer drug Eligard.

Astellas expects stronger growth for Eligard in EU  -  Mar 23, 2007
Pharma Times (subscription),Japanese drugmaker Astellas Pharma expects strong growth in European sales of Eligard (leuprolide) with the launch of a unique six-monthly injection of this

MediGene's Six-Months Dosage of the Cancer Drug Eligard® Launched ...  -  Mar 1, 2007
PharmaLive.com (press release),MediGene AG (Frankfurt, Prime Standard: MDG) announced that the six-months dosage of Eligard® for the treatment of prostate cancer is now available in

Is QLT the Comeback Kid?  -  Feb 26, 2007
Motley FoolSales of Eligard have grown strongly to combat the reduced royalties from macular degeneration drug Visudyne. And now that QLT put the Eligard patent

First six-month cancer dosage introduced to Europe  -  Mar 1, 2007
In-PharmaTechnologist.com,01/03/2007 - MediGene's six-month dosage of its prostate cancer drug Eligard (leuprolide acetate) is now available in Germany, the company announced today.

MediGene's Six-Months Dosage of the  -  Feb 28, 2007
Ad-Hoc-News (Pressemitteilung),Eligard® is the only prostate cancer drug in. Europe that is available as a six-months dosage. The drug is sold by. MediGene's partner Astellas Pharma.

QLT settles 2001 lawsuits over Visudyne  -  Mar 5, 2007
Toronto Star,The settlement with Massachusetts Eye and Ear Infirmary follows a settlement by the company regarding a patent infringement lawsuit over its Eligard

QLT Settles MEEI Lawsuit With Respect to the '303 Patent  -  Mar 5, 2007
CNW Telbec (Communiqués de presse),Eligard is a registered trademark of Sanofi-Synthelabo Inc. QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto

QLT expects Visudyne sales to fall in 2007, Eligard sales at US ...  -  Feb 22, 2007
Canada.com,QLT said it expects Eligard sales will range from $140 million to $160 million. Research-and-development expenses for 2007, excluding up-front licensing

QLT Announces 2006 Results  -  Feb 22, 2007
PharmaLive.com (press release),For the full year 2006, worldwide Eligard(R) sales were $120.7 million, an increase of 37.7% over the full year 2005. Total revenues were $175.1 million in

QLT expects Visudyne annual sales to fall, stabilize around US$250 ...  -  Feb 22, 2007
Canada.com,QLT said it expects Eligard sales will range from $140 million to $160 million this year. In 2006, Eligard sales were $120.7 million, an increase of 38 per

QLT says unit to pay $112.5 mln to settle Eligard patent suit  -  Feb 9, 2007
Reuters Canada,TO: Quote) said its subsidiary will pay $112.5 million to settle a patent infringement lawsuit related to its prostrate cancer drug Eligard.

QLT sees continuing decline in sales of main drug  -  Feb 22, 2007
CBC News,But on the upside, QLT said worldwide sales of its prostate drug Eligard were $120.7 million US last year, up about 38 per cent from 2005, and it expects

QLT narrows losses  -  Feb 22, 2007
Toronto Star,..."Also, we were very pleased with the performance of Eligard in 2006, reflecting strong growth in Europe following the product's launch in many key markets.

Market Report -- In Play (QLTI)  -  Feb 22, 2007
MSN MoneyBased on recent events and current trends in Eligard sales, co estimates Eligard sales will range from $140-160 mln in 2007. R&D expenses for 2007,

UPDATE 2-QLT hit by weak Visudyne sales, pain seen lingering  -  Feb 22, 2007
ReutersThe 2006 quarter included a charge in connection with the settlement of a patent infringement case involving its prostate cancer drug Eligard.

QLT Pays Up  -  Feb 13, 2007
Motley FoolThis settlement clears the way for QLT and marketing partner Sanofi-Aventis (NYSE: SNY) to continue selling Eligard in the US and Canada without having to

QLT USA signs agreement with TAP to settle United States patent ...  -  Feb 9, 2007
CNW Telbec (Communiqués de presse),In addition, to avoid further disputes regarding Eligard sales in the United States and Canada, each of TAP, Takeda, Wako and Abbott Laboratories,

QLT, Sanofi to Pay TAP $157.5 Million to Settle Suit (Update3)  -  Feb 9, 2007
BloombergQLT, based in Vancouver, and Paris-based Sanofi will get a license to all TAP patents related to Eligard in the US QLT said the agreement doesn't resolve

QLT, Sanofi to Pay TAP $157.5 Million to Settle Suit (Update1)  -  Feb 9, 2007
BloombergQLT and Sanofi will get a license to all TAP patents related to Eligard in the US The agreement doesn't resolve related litigation in Germany,

TAP, QLT USA settle patent suit  -  Feb 9, 2007
United Press International...then a company called Atrix, claiming Atrix infringed TAP's patent through sales of Atrix's Eligard-brand products in the United States and Canada.

Ranbaxy unveils two new drugs  -  Jan 29, 2007
Economic Times,Niftran 100mg Capsules developed using the company's R&D capabilities and Eligard 22.5mg & 45mg, in-licensed from QLT Inc, USA, have been launched in the

Ranbaxy launches two NDDS Urology products in India Niftran ...  -  Jan 29, 2007
Equity Bulls,Niftran 100mg Capsules (Nitrofurantoin modified release) developed using the Company's R&D capabilities & Eligard 22.5mg & 45mg (Leuprolide Depot),

QLT shares trade lower after TAP patent lawsuit settlement last week  -  Feb 12, 2007
Canada.com,The settlement did not affect the ongoing case in Germany started by Takeda and Wako German affiliates against QLT's European licensees of its Eligard

Fording, Penn West, QLT, UrAsia : Canadian Equity Preview  -  Feb 12, 2007
BloombergTAP Pharmaceutical Products Inc. sued QLT and Sanofi in 2003, claiming that Eligard infringed a TAP patent. QLT will pay $112.5 million and Sanofi will pay

Ranbaxy launches 2 NDDS Urology products in India  -  Feb 1, 2007
Moneycontrol.com,Commenting on the launch, Mr. Sanjeev I. Dani, Senior Vice President and Regional Director, Asia & CIS, Ranbaxy, said “The launch of Niftran and Eligard

Ranbaxy launches two urology products in India  -  Jan 29, 2007
Hindu,29 (PTI): Pharma major Ranbaxy Laboratories today announced the launch of two urology products -- Niftran capsules and Eligard -- in multiple dosage in the

Ranbaxy launches two NDDS Urology products in India  -  Jan 30, 2007
domain-B,Niftran 100mg capsules (nitrofurantoin modified release) developed using the company's R&D capabilities and Eligard 22.5mg and 45mg (leuprolide depot),

Ranbaxy launches two urology products in India  -  Jan 29, 2007
Afternoon Dispatch & Courier,Pharma major Ranbaxy Laboratories today announced the launch of two urology products — Niftran capsules and Eligard — in multiple dosages in the domestic

QLT to Pay $112.5M in Patent Settlement  -  Feb 9, 2007
Houston Chronicle,The settlement also allows QLT a non-exclusive, perpetual royalty-free license to use and sell any of the company's past and future patents to make Eligard

Canada: QLT, Sanofi settle suit  -  Feb 10, 2007
Ottawa Citizen (subscription),...and Sanofi-Aventis SA agreed to pay a total of $157.5 million US to end a patent suit so they can continue to sell the prostate cancer drug Eligard.

Ranbaxy in-licences urology drug from US firm  -  Jan 29, 2007
Business Standard,Sanjeev I Dani, senior vice president and regional director, Asia & CIS, Ranbaxy, said: "The launch of Niftran and Eligard reinforces our commitment in the

Ranbaxy launches two NDDS products in India  -  Jan 29, 2007
Myiris.com,The two products launched in the Indian market are Niftran 100mg capsules, using the company`s R&D capabilities and Eligard 22.5mg & 45mg, in-licensed from

QLT downgraded to "reduce"  -  Feb 12, 2007
newratings.comQLT and partner Sanofi-Synthelabo have finalized a settlement with TAP Pharmaceuticals associated with the outstanding litigation of QLT's Eligard product,

QLT: $112.5m settlement  -  Feb 11, 2007
Vancouver Province (subscription),TAP Pharmaceutical Products Inc. to settle a patent-infringement lawsuit concerning Eligard, a hormonal therapy used to treat advanced prostate cancer.

Drug maker settles suit  -  Feb 10, 2007
Vancouver Sun (subscription),Vancouver's QLT Inc. announced Friday it is paying out $112.5 million US to settle its long-standing patent dispute over its prostate cancer drug Eligard in

MediGene to Present at the BIO CEO &  -  Feb 8, 2007
Ad-Hoc-News (Pressemitteilung),...the European market (Eligard® for the treatment of prostate cancer). European countries. Several other drug candidates are in clinical. development.

TSX weighed down by energy stocks  -  Feb 22, 2007
Toronto Star,...million from $370.4 million in the prior-year period despite taking a $112.5-million charge to settle litigation over its Eligard prostate cancer drug.

Biotech Day In Review: Sanofi Loses Lovenox Patent  -  Feb 11, 2007
Seeking Alpha,As part of the settlement, the two companies will have the right to profit from Eligard in the future. QLT actually moved higher on the news,

Market Report -- In Play (QLTI)  -  Feb 9, 2007
MSN Money...by TAP and its co-plaintiffs in 2003 in which TAP and its co-plaintiffs claimed that Atrix's (now QLT USA's) Eligard(R) products infringed US patent no.

MediGene to Present at the BIO CEO & Investor Conference in New York  -  Feb 8, 2007
PharmaLive.com (press release),MediGene possesses a mature drug pipeline with a drug available on the European market (Eligard® for the treatment of prostate cancer).

MediGene to Present at the BIO CEO & Investor Conference in New York  -  Feb 8, 2007
WebWire (press release),MediGene possesses a mature drug pipeline with a drug available on the European market (Eligard®). A second drug (Polyphenon® E Ointment) has been approved

Tolmar in sale-leaseback deal to snap up QLT USA  -  Feb 6, 2007
In-PharmaTechnologist.com,Sales of Eligard (leuprolide), approved for the palliative treatment of advanced prostate cancer, were temporarily suspended following patent litigation for

QLT Announces Visudyne Sales for Fourth Quarter and Fiscal Year 2006  -  18 Jan 2007
PharmaLive.com (press release),Eligard is a registered trademark of Sanofi-Synthelabo Inc. QLT Inc. is listed on The Nasdaq Stock Market under the trading symbol

QLT announces divestment of QLT USA, Inc.'s generic dermatology ...  -  Dec 27, 2006
Drug Newswire (press release),Eligard(R) will continue to be manufactured in the Fort Collins plant under the terms of a supply agreement between QLT USA and Tolmar.

QLT Inc. sells US generic dermatology and manufacturing business ...  -  Dec 22, 2006
Canada.com,But the company increased its annual sales guidance for Eligard, a treatment for prostate cancer, from between US$100 million and US$115 million to between

QLT completes sale of Fort Collins operations  -  Dec 23, 2006
North Colorado Business Report,Eligard, a prostate cancer product developed by Atrix Laboratories Inc. before it was acquired by Vancouver-based QLT in 2004, will continue to be

MediGene's Acquisition of a License on Oracea Gives the Signal for ...  -  Dec 20, 2006
PharmaLive.com (press release),MediGene is a trademark of MediGene AG, AtrigelTM® is a registered trademark of QLT USA, Inc., Eligard® is a trademark of Sanofi-Synthelabo Inc..

MediGene's Drug Eligard Launched in Italy  -  Dec 18, 2006
PharmaLive.com (press release),18, 2006--The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announces that its drug Eligard® for the treatment of advanced prostate cancer is

Eligard(R) six-month formulation approved in Germany  -  Dec 3, 2006
Drug Newswire (press release),In September 2005, Astellas Pharma Inc. filed a Marketing Authorization Application for the Eligard (45 mg) six-month product with the German pharmaceutical

QLT announces divestment of QLT USA, Inc.'s generic dermatology ...  -  Dec 22, 2006
CNW Telbec (Communiqués de presse),Eligard(R) will continue to be manufactured in the Fort Collins plant under the terms of a supply agreement between QLT USA and Tolmar.

Germany clears Medigene to sell 6 mth dosage of Eligard prostate ...  -  Dec 1, 2006
Forbes,MARTINSRIED, Germany (AFX) - Medigene AG said it has been granted approval in Germany to sell a six-month dosage of its prostate cancer drug Eligard.

QLT Inc. sells US generic dermatology and manufacturing business ...  -  Dec 22, 2006
Canada.com,But the company increased its annual sales guidance for Eligard, a treatment for prostate cancer, from between US$100 million and US$115 million to between

Germany OK's QLT's cancer treatment  -  Dec 1, 2006
United Press InternationalEligard's one-month and three-month formulations have previously been approved in Germany and other European countries. QLT said it expects reimbursement

Valera Jumps on Buyout Deal  -  Dec 12, 2006
BusinessWeekDespite the room for expansion, Valera faces deep-pocketed competitors like French giant Sanofi-Aventis' (SNY) Eligard treatment.

Dr. Bruce Carter joins QLT's board of directors  -  Nov 29, 2006
CNW Telbec (Communiqués de presse),Eligard is a registered trademark of Sanofi-Synthelabo Inc. QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto

Market Report -- In Play (WIRES)  -  Dec 1, 2006
MSN MoneyQLT USA, a subsidiary of QLT (QLTI) announces that the Eligard 45 mg six-month formulation has been approved in Germany.

QLT Signs Research Collaboration and Option Agreement with Wilmer ...  -  Dec 20, 2006
PharmaLive.com (press release),Eligard is a registered trademark of Sanofi-Synthelabo Inc. QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on the Toronto

QLT completes sale of Fort Collins operations  -  Dec 23, 2006
North Colorado Business Report,Eligard, a prostate cancer product developed by Atrix Laboratories Inc. before it was acquired by Vancouver-based QLT in 2004, will continue to be

MediGene's Acquisition of a License on Oracea Gives the Signal for ...  -  Dec 20, 2006
PharmaLive.com (press release),MediGene is a trademark of MediGene AG, AtrigelTM® is a registered trademark of QLT USA, Inc., Eligard® is a trademark of Sanofi-Synthelabo Inc..

German Stocks Decline, Led by SAP, E.ON and Deutsche Telekom  -  Dec 1, 2006
BloombergThe biotechnology company said the six-month dosage of its prostate cancer drug Eligard has been granted approval by the German regulator BfArM (Federal

Sección internacional  -  Dec 1, 2006
Bolsamania.com,...(PRN) - Eligard(R) six-month formulation approved in Germany ... [+]. (PRN) - European Governments Invest an Additional euro 26 Million in AIDS Vaccine

QLT announces positive findings from Phase IV G6PD deficiency ...  Nov 7, 2006
...of innovative drug therapies with our two unique technology platforms, photodynamic therapy and Atrigel®, to create products such as Visudyne® and Eligard®. ... -Yahoo! News (press release) QLT announces Q3 results for 2006, updates guidance, and ...  Oct 26, 2006
Eligard® worldwide sales for the third quarter were $34.0 million, up 60.6% from the third quarter of 2005. Eligard sales in the ... -Yahoo! News (press release) QLT Quickly Losing Traction  Oct 26, 2006
There was one bright spot in the quarter for QLT, though. Eligard sales were up 61% year over year, to $34 million. QLT shareholders ... -MSNBC QLT cuts 80 jobs and reports Q3 loss of US$3.8M, versus year-ago ...  Oct 26, 2006
But the company increased its annual sales guidance for Eligard, a treatment for prostate cancer, from between $100 million and $115 million to between $110 ... -CBC News, QLT slashing staff, cutting R&D costs  Oct 27, 2006
While the company isn't actively trying to sell its Eligard prostate cancer drug, he said that "if a good offer came along, we'd entertain it.". ... -Globe and Mail, QLT cuts 80 jobs after posting loss  Oct 26, 2006
But, the firm said Thursday it is increasing its annual sales guidance for the drug Eligard from $100-million to $115-million to a range of $110-million to $120 ... -Globe and Mail, QLT loss leads to cuts  Oct 26, 2006
...its. annual sales guidance for the drug Eligard from $100 million-$115 million to a range of $110 million-$120 million. Earnings ... -Toronto Star, Biotech QLT to cut 80 jobs after Q3 loss  Oct 27, 2006
...to a four-cents-a-share loss in the third quarter, compared to earnings per share of 14 cents a year ago, were its legal expenses in its Eligard patent dispute ... -Vancouver Sun (subscription), Prostate Cancer Hormone Therapy May Have Unwelcome Side Effects  Oct 30, 2006
...agonists. Common drugs in this class include leuprolide (Lupron, Viadur, Eligard), goserelin (Zoladex), and triptorelin (Trelstar). ... -ACS News Center, Hormones seen as risky regimen for prostate cancer  Oct 25, 2006
The drugs, sold under names like Lupron, Zoladex, Eligard , and Vantas, are big business for both the companies that make them and the urologists who ... -Boston Globe, QLT cuts annual forecast after Q3 sales of Visudyne fall 39.3% to ...  Oct 19, 2006
...and a fight with TAP Pharmaceutical Products Inc., which sued QLT and its partner, a unit of Sanofi-Aventis Group, alleging its drug Eligard, a treatment for ... -CBC News, QLT Announces Final Results of Tender Offer  Sep 14, 2006
...of innovative drug therapies with our two unique technology platforms, photodynamic therapy and Atrigel®, to create products such as Visudyne® and Eligard®. ... -Yahoo! News

QLT Announces Preliminary Results of Tender Offer  Sep 11, 2006
...drug therapies with our two unique technology platforms, photodynamic therapy and Atrigel(R), to create products such as Visudyne(R) and Eligard(R). For more ... -PharmaLive.com

Avidex Moves To Next Stage Via €50M MediGene Merger  Sep 5, 2006
Enter MediGene, founded in 1996 as a gene therapy company but subsequently transmuted into a specialty pharmaceutical company with the product Eligard on the ... -BioWorld Online

Avidex’ portfolio includes RhuDex®, a drug candidate with a ...  Aug 31, 2006
...and the cancer drugs derived from our EndoTAG-platform we are well positioned to further develop our business beyond our mature products Eligard and Polyphenon ... -Oxfordshire Bioscience Network

Cougar Biotechnology Appoints Dr. Russell Ellison to Board of ...  Sep 11, 2006
Synthelabo, where he was responsible for several key oncology products including Eloxatin (oxaliplatin) for colorectal cancer and Eligard (leuprolide acetate ... -Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional